Integer (NYSE:ITGR) Reaches New 52-Week High – Still a Buy?

Integer Holdings Co. (NYSE:ITGR) shares reached a new 52-week high during trading on Monday . The stock traded as high as $142.00 and last traded at $142.00, with a volume of 367 shares. The stock had previously closed at $138.11.

Analyst Upgrades and Downgrades

ITGR has been the topic of several recent research reports. KeyCorp increased their target price on Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. Bank of America raised their target price on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 1st. Citigroup upped their price target on Integer from $124.00 to $130.00 and gave the stock a “neutral” rating in a report on Tuesday, October 1st. Truist Financial decreased their target price on Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, Benchmark increased their price objective on Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $139.75.

Integer Trading Up 0.8 %

The business’s 50 day simple moving average is $130.22 and its 200 day simple moving average is $123.57. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. The company has a market capitalization of $4.67 billion, a price-to-earnings ratio of 42.63, a price-to-earnings-growth ratio of 1.98 and a beta of 1.09.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The firm had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. During the same period in the previous year, the firm posted $1.27 EPS. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. Research analysts anticipate that Integer Holdings Co. will post 5.34 EPS for the current year.

Hedge Funds Weigh In On Integer

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Integer by 0.6% during the first quarter. Vanguard Group Inc. now owns 3,826,088 shares of the medical equipment provider’s stock worth $446,428,000 after acquiring an additional 23,382 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its position in Integer by 4.0% during the first quarter. CANADA LIFE ASSURANCE Co now owns 35,068 shares of the medical equipment provider’s stock valued at $4,091,000 after buying an additional 1,361 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Integer by 6.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,031 shares of the medical equipment provider’s stock worth $2,221,000 after purchasing an additional 1,219 shares during the period. Hancock Whitney Corp acquired a new stake in shares of Integer during the 1st quarter valued at $203,000. Finally, Virtu Financial LLC purchased a new position in Integer in the first quarter valued at about $298,000. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.